Brief: Regeneron Pharmaceuticals Says Lynozyfic Monotherapy In Newly Diagnosed Multiple Myeloma Shows Impressive Responses
07/12/2025 21:33
Dec 7 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: LYNOZYFIC™ (LINVOSELTAMAB) MONOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) SHOWS IMPRESSIVE RESPONSES, SUPPORTING RATIONALE AS A POTENTIAL FOUNDATION IN FRONTLINE TREATMENT Source text: ID:nGNX2fdvtV Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)